The store will not work correctly when cookies are disabled.
JavaScript seems to be disabled in your browser. For the best experience on our site, be sure to turn on Javascript in your browser.
(R)-2-(4-hydroxybicyclo[2.2.2]octan-1-yl)-8-methyl-4-propyl-7,8-dihydro-1H-imidazo[1,2-g]purin-5(4H)-one ID: ALA384279
PubChem CID: 135428628
Max Phase: Preclinical
Molecular Formula: C19H27N5O2
Molecular Weight: 357.46
Molecule Type: Small molecule
Associated Items:
Names and Identifiers Canonical SMILES: CCCN1C(=O)N2C[C@@H](C)N=C2c2[nH]c(C34CCC(O)(CC3)CC4)nc21
Standard InChI: InChI=1S/C19H27N5O2/c1-3-10-23-15-13(14-20-12(2)11-24(14)17(23)25)21-16(22-15)18-4-7-19(26,8-5-18)9-6-18/h12,26H,3-11H2,1-2H3,(H,21,22)/t12-,18?,19?/m1/s1
Standard InChI Key: OWEIZFWQMOUOHL-PIHIASKNSA-N
Molfile:
RDKit 2D
26 30 0 0 1 0 0 0 0 0999 V2000
-3.7958 -9.1250 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-3.0838 -9.5333 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
-2.3718 -8.3000 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-2.3718 -9.1260 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-1.5862 -9.3814 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
-1.1006 -8.7131 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-1.5862 -8.0448 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
-3.7919 -8.2977 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
-3.0838 -7.8833 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-3.2591 -7.0818 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
-4.0756 -7.0008 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-4.4048 -7.7523 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-3.0843 -10.3583 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-3.7989 -10.7705 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-4.5132 -10.3576 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-0.2756 -8.7131 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
0.1342 -9.4347 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
0.9556 -9.4367 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
1.3720 -8.7241 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
0.9607 -8.0078 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
0.1331 -8.0041 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
0.5708 -8.2375 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
0.5708 -9.0167 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-4.5107 -9.5368 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
2.1958 -8.7208 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
-4.4924 -6.2888 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
12 8 1 0
3 9 1 0
2 13 1 0
4 5 1 0
13 14 1 0
5 6 2 0
14 15 1 0
6 7 1 0
6 16 1 0
16 17 1 0
7 3 1 0
8 9 1 0
3 4 2 0
8 1 1 0
16 21 1 0
17 18 1 0
18 19 1 0
19 20 1 0
20 21 1 0
1 2 1 0
16 22 1 0
2 4 1 0
22 23 1 0
23 19 1 0
9 10 2 0
1 24 2 0
10 11 1 0
19 25 1 0
11 12 1 0
11 26 1 1
M END Associated Targets(Human) Associated Targets(non-human) Molecule Features Natural Product: NoOral: NoChemical Probe: NoParenteral: NoMolecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: NoChirality: NoAvailability: NoProdrug: No
Drug Indications MESH ID MESH Heading EFO IDs EFO Terms Max Phase for Indication References
Mechanisms of Action Mechanism of Action Action Type target ID Target Name Target Type Target Organism Binding Site Name References
Calculated Properties Molecular Weight: 357.46Molecular Weight (Monoisotopic): 357.2165AlogP: 2.55#Rotatable Bonds: 3Polar Surface Area: 84.82Molecular Species: NEUTRALHBA: 4HBD: 2#RO5 Violations: ┄HBA (Lipinski): 7HBD (Lipinski): 2#RO5 Violations (Lipinski): ┄CX Acidic pKa: 10.29CX Basic pKa: 5.11CX LogP: 1.89CX LogD: 1.89Aromatic Rings: 1Heavy Atoms: 26QED Weighted: 0.87Np Likeness Score: 0.01
References 1. Vu CB, Kiesman WF, Conlon PR, Lin KC, Tam M, Petter RC, Smits G, Lutterodt F, Jin X, Chen L, Zhang J.. (2006) Tricyclic imidazoline derivatives as potent and selective adenosine A1 receptor antagonists., 49 (24): [PMID:17125265 ] [10.1021/jm060539t ]